One Turn Open the globe →Globe →

Health · Hong Kong · China ·

FDA rejects China's lung cancer drug ivonescimab

The US FDA rejected Akeso's cancer drug ivonescimab. Akeso shares fell as much as 31.8% in Hong Kong. The drug had become a symbol of China's rise in drug development.

Why it matters

The decision is a setback for Chinese drugmakers seeking US approval.

Background

Akeso is a Hong Kong-listed Chinese biotech company.

The story so far

  1. US FDA rejects China lung cancer drug
  2. FDA rejects China's lung cancer drug ivonescimab

Follow the whole story →

Sources

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.

See it on the globe →All of Nov 16's stories

More on health